Scinai Immunotherapeutics Ltd. – NASDAQ:SCNI

Add to watchlist

$1.52

-1.81

-54.49%

Market closed

Open in about 3 hours

-17.73%

month

-17.73%

quarter

+384.06%

year

Market Cap	2.94M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-1.90

Revenue	N/A
EBITDA	-9.33M
Income	-6.5M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI): Profit margin
Mar 2023	0	-3.51M
Jun 2023	0	-3.76M
Sep 2023	0	3.10M
Dec 2023	0	-2.33M

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI): Earnings per share (EPS)
2023-08-11	-0.91	-1.11
2023-10-31	-0.99	-0.66

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI): Debt to assets
Mar 2023	23292000	28.10M	120.65%
Jun 2023	19897000	27.00M	135.74%
Sep 2023	18582000	21.27M	114.49%
Dec 2023	17472000	22.04M	126.15%

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI): Cash Flow
Mar 2023	-3.05M	-6K	0
Jun 2023	-2.87M	-377K	0
Sep 2023	-2.22M	-20K	1.08M
Dec 2023	-1.22M	-234K	0

Scinai Immunotherapeutics Ltd. alternative data

Scinai Immunotherapeutics Ltd.
Employees

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI): Employee count
Dec 2023	33
Jan 2024	33
Feb 2024	33
Mar 2024	33
Apr 2024	33
May 2024	33
Jun 2024	33
Jul 2024	31

Scinai Immunotherapeutics Ltd.
Latest News

Monday, 16 December 2024
09:25	Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.	prnewswire.com
Thursday, 5 December 2024
08:25	Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board	prnewswire.com
Wednesday, 27 November 2024
08:00	Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board	prnewswire.com
Friday, 22 November 2024
07:15	Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million	prnewswire.com
Thursday, 31 October 2024
06:59	Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024	prnewswire.com
Monday, 16 September 2024
07:00	Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies	prnewswire.com
Monday, 9 September 2024
11:12	IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.	globenewswire.com
Thursday, 29 August 2024
06:31	Scinai Regains Full Compliance with Nasdaq Listing Requirements	prnewswire.com
Wednesday, 21 August 2024
08:45	Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000	prnewswire.com
Tuesday, 20 August 2024
14:28	Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript	seekingalpha.com
09:30	Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder	prnewswire.com
Thursday, 15 August 2024
07:00	Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23	prnewswire.com
Tuesday, 13 August 2024
07:00	Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity	prnewswire.com
Tuesday, 23 July 2024
07:00	Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb	prnewswire.com
Monday, 15 July 2024
12:31	Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results	invezz.com
12:04	Why Is Scinai Immunotherapeutics (SCNI) Stock Up 56% Today?	investorplace.com
07:00	Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model	prnewswire.com
Monday, 8 July 2024
08:14	Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity	prnewswire.com
Wednesday, 3 July 2024
09:32	Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements	prnewswire.com
Tuesday, 2 July 2024
08:12	Scinai Publishes Q1 2024 Financial Results and Provides Business Update	prnewswire.com
Monday, 17 June 2024
07:56	Why Is Scinai Immunotherapeutics (SCNI) Stock Up 88% Today?	investorplace.com
Thursday, 13 June 2024
07:00	Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.	prnewswire.com
Friday, 7 June 2024
07:00	Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement	prnewswire.com
Friday, 24 May 2024
16:01	Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance	prnewswire.com
Wednesday, 15 May 2024
16:01	Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update	prnewswire.com

Frequently Asked Questions (FAQ)

What's the price of Scinai Immunotherapeutics Ltd. stock today?

One share of Scinai Immunotherapeutics Ltd. stock can currently be purchased for approximately $1.52.
When is Scinai Immunotherapeutics Ltd.'s next earnings date?

Unfortunately, Scinai Immunotherapeutics Ltd.'s (SCNI) next earnings date is currently unknown.
Does Scinai Immunotherapeutics Ltd. pay dividends?

No, Scinai Immunotherapeutics Ltd. does not pay dividends.
How much money does Scinai Immunotherapeutics Ltd. make?

Scinai Immunotherapeutics Ltd. has a market capitalization of 2.94M. Scinai Immunotherapeutics Ltd. made a loss 6.5M US dollars in net income (profit) last year or -$0.66 on an earnings per share basis.
What is Scinai Immunotherapeutics Ltd.'s stock symbol?

Scinai Immunotherapeutics Ltd. is traded on the NASDAQ under the ticker symbol "SCNI".
What is Scinai Immunotherapeutics Ltd.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Scinai Immunotherapeutics Ltd.?

Shares of Scinai Immunotherapeutics Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Scinai Immunotherapeutics Ltd. have?

As Jul 2024, Scinai Immunotherapeutics Ltd. employs 31 workers, which is 6% less then previous month and 6% less then previous quarter.
When Scinai Immunotherapeutics Ltd. went public?

Scinai Immunotherapeutics Ltd. is publicly traded company for more then 10 years since IPO on 11 May 2015.
What is Scinai Immunotherapeutics Ltd.'s official website?

The official website for Scinai Immunotherapeutics Ltd. is scinai.com.
How can i contact Scinai Immunotherapeutics Ltd.?

Scinai Immunotherapeutics Ltd. can be reached via phone at +972 8 930 2529.

Scinai Immunotherapeutics Ltd.

scinai.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

+972 8 930 2529

Jerusalem BioPark Building
Jerusalem,

CIK: 0001611747
ISIN: US09073Q2049
: